Sensei Biotherapeutics (NASDAQ:FTH) Releases Earnings Results, Misses Expectations By $0.13 EPS

Sensei Biotherapeutics (NASDAQ:FTH) posted its quarterly earnings results on Tuesday. The company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.13), Zacks reports.

Sensei Biotherapeutics Price Performance

NASDAQ:FTH opened at $20.44 on Wednesday. The firm has a market capitalization of $528.20 million, a price-to-earnings ratio of -0.14 and a beta of -0.15. Sensei Biotherapeutics has a 12-month low of $7.45 and a 12-month high of $42.14. The business has a 50-day simple moving average of $28.24.

Analysts Set New Price Targets

FTH has been the subject of a number of analyst reports. Oppenheimer initiated coverage on Sensei Biotherapeutics in a research note on Tuesday, July 28th. They set an “outperform” rating and a $60.00 target price for the company. Wall Street Zen lowered shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a report on Saturday, September 26th. Needham & Company LLC started coverage on Sensei Biotherapeutics in a report on Friday, August 21st. They set a “buy” rating and a $56.00 price objective on the stock. Lifesci Capital upgraded shares of Sensei Biotherapeutics to a “strong-buy” rating in a research note on Thursday, October 15th. Finally, Raymond James Financial assumed coverage on Sensei Biotherapeutics in a research note on Friday, July 31st. They set an “outperform” rating and a $56.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Sensei Biotherapeutics currently has a consensus rating of “Buy” and an average price target of $56.25.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is designed to activate and direct the immune system against tumors, with an emphasis on treatments that may address immune-suppressive mechanisms in the tumor microenvironment.

Sensei’s pipeline has included SNS-101, an investigational antibody targeting VISTA, an immune checkpoint believed to limit anti-tumor immune responses, and SNS-301, an investigational cancer vaccine developed using the company’s ImmunoPhage platform.